Approval · Notice of Compliance 32710 · 2024
PRISTIQ: Notice of Compliance 32710
Issued February 14, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32710
- Date
- February 14, 2024
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To align the overdose section of the Product Monograph (PM) with the proposed changes to the company core data sheet.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRISTIQ | Not yet assigned | — |
Medicinal ingredients
- DESVENLAFAXINE SUCCINATE 50 MG per TAB
- DESVENLAFAXINE SUCCINATE 100 MG per TAB